Walk into a hearing clinic and you will be shown four or five brand names. Search online and you will find twenty. It feels like a crowded market with lots of independent competitors, which is exactly what you would want when you are about to spend a few thousand dollars.
It is not quite that crowded. Nearly every well-known hearing aid brand in the world belongs to one of five parent companies. Once you know which name belongs to whom, a lot of confusing things about hearing aid pricing suddenly make sense. This is a plain-language map of who actually makes hearing aids in 2026, and what it means for what you pay.
The Big Five
Industry analysts have used the term Big Five for years to describe the manufacturers that dominate the category: Sonova, Demant, WS Audiology, GN and Starkey. Reporting by The Capitol Forum, citing the American Economic Liberties Project, put their combined grip at an estimated 90 percent of the global hearing aid market and 84 percent of the U.S. market. Four of the five are headquartered outside the United States.
| Parent company | Home country | Brands you have heard of |
|---|---|---|
| Sonova | Switzerland | Phonak, Unitron, Sennheiser hearing |
| Demant | Denmark | Oticon, Philips hearing, Sonic, Bernafon |
| GN | Denmark | ReSound, Beltone, Jabra Enhance |
| WS Audiology | Germany | Signia, Widex, Rexton, legacy Siemens |
| Starkey | United States | Starkey, Audibel |
If you have been comparing Phonak against Unitron, or Oticon against Philips, or ReSound against Beltone, you have been comparing two product lines from the same parent. That is not a scandal. Car companies do the same thing. But it is worth knowing before you treat a second opinion from a different brand as an independent one.
Skip the markup, keep the performance.
Shop Panda® Quantum — $349What people are actually paying
HearingTracker runs an annual survey asking buyers what they paid. Rolled up by parent company, the 2026 responses tracked closely with independent market estimates: Sonova brands accounted for about 25 percent of respondents, Demant-linked brands about 17 percent, GN brands about 17 percent, WS Audiology about 12 percent and Starkey about 6 percent.
The prices those respondents reported are the part worth studying:
| Brand | Owned by | Reported average paid |
|---|---|---|
| Widex | WS Audiology | $4,185 |
| Phonak | Sonova | $4,132 |
| Starkey | Starkey | $3,893 |
| Oticon | Demant | $3,840 |
| ReSound | GN | $3,327 |
| Signia | WS Audiology | $3,256 |
| Beltone | GN | $1,755 |
| Philips | Demant license | $1,696 |
| Rexton | WS Audiology | $1,566 |
| Jabra | GN | $1,552 |
| Kirkland Signature | Retail house brand | $1,377 |
Look down that column and something jumps out. GN owns both ReSound at $3,327 and Jabra at $1,552. WS Audiology owns both Signia at $3,256 and Rexton at $1,566. Same parent, same engineering teams, roughly half the price. The variable that changed is not the company that built the device. It is the channel it was sold through.
Panda® Quantum — $349
5-year warranty, 45-day risk-free trial, free shipping. FDA-OTC certified.
See Panda® Quantum →Why the same chip costs two different prices
The Big Five are what economists call vertically integrated. They do not just manufacture devices. Several of them also own or control the retail clinics that sell those devices, and four of the five operate what the industry calls hearing benefits managers, which are insurance intermediaries that contract with commercial and Medicare Advantage plans to determine which providers are in network and which devices are covered.
So when you pay $4,000 for a pair of premium prescription hearing aids, you are not paying $4,000 for silicon. You are paying for the chip plus the clinic's rent, the fitting appointments, the follow-up visits, the sales commission and the layer of insurance administration sitting on top of all of it. Some of that is real value, especially the professional fitting, which genuinely matters for complex or severe hearing loss. Some of it is simply the cost of a long distribution chain.
Consolidation is still underway. Amplifon, the Italian company that operates one of the largest hearing care retail networks in the world, is reportedly set to acquire GN's hearing business for roughly $2.64 billion by the end of 2026. If that closes, one of the biggest retailers in the category becomes one of the biggest manufacturers too.
The rebranding wrinkle
There is one more layer that trips up comparison shoppers. Several private-label brands sold through clinic networks and big-box retailers are the same hardware as a name brand with a different label on the shell. Take an Oticon device, remove the Oticon name, apply a private-label name, and you have a second brand in the comparison chart that is not actually a second product.
This is why brand-satisfaction surveys can produce strange results, with a house brand ranking well below the identical name-brand device. The device did not change. The buying experience, the price and the support did.
Where over-the-counter changed the math
Congress passed the Over-the-Counter Hearing Aid Act in 2017. The FDA finalized the rule in 2022, creating a genuine regulated category of hearing aids that adults with perceived mild to moderate hearing loss can buy without a prescription, an exam or a fitting appointment. That single rule removed most of the distribution chain described above.
The Big Five noticed. Research published in Frontiers in Audiology and Otology documented that four of the five moved into OTC, mostly through consumer audio brand names they already owned: GN through Jabra, Sonova through Sennheiser, Starkey through its own OTC line, and WS Audiology through Widex and Signia arrangements. Demant was the last holdout at the time of that analysis. When the incumbents follow you into a category, it is usually a sign the category works.
Clear conversation, no appointment required.
Get Panda® Quantum — $349Where Panda fits on this map
Panda is not one of the Big Five and does not pretend to be. We build FDA-OTC certified hearing aids and sell them straight to you, which is the entire reason a device with serious processing can land at $349 instead of several thousand.
For people who struggle most when the room gets loud, Panda® Quantum is our best model for clear speech in noisy environments. It runs a short self-hearing test on your phone, applies frequency-level personalization to match your own hearing profile, and uses adaptive noise reduction so that a restaurant gets quieter without the voice across from you getting quieter too. There is no clinic visit, no fitting fee and no waiting list. You put them on and go.
To be clear about the limits, because it matters: OTC devices including ours are designed for adults with perceived mild to moderate hearing loss. If your loss is severe or profound, if it came on suddenly, if it affects only one ear, or if you have pain or drainage, a licensed audiologist and the prescription products the Big Five make are the correct path. This article is not an argument that clinics are unnecessary. It is an argument that you should know what portion of your bill is device and what portion is distribution.
Common questions
Is one of the Big Five clearly the best?
No, and anyone who tells you otherwise is selling something. Each has genuine engineering strengths, and independent reviewers rate flagship models from all five highly. The more useful question is which device suits your hearing profile and your budget, not which logo is on it.
If GN makes both ReSound and Jabra, why is Jabra so much cheaper?
Because Jabra is sold through a direct and telehealth channel while ReSound runs through clinics. That is the clearest illustration in the whole market of how much of a hearing aid price is distribution rather than hardware.
Does a smaller company mean lower quality?
Not automatically. The FDA's OTC rule sets performance and labeling requirements that any device in the category has to meet, whoever makes it. Judge a device on its processing, its fit, its warranty and its return policy rather than the size of the company behind it.
Should I still see an audiologist?
If you can, a baseline hearing test is always worth having, and it costs little or nothing at many clinics. Knowing your audiogram makes every subsequent decision easier, including whether an OTC device is appropriate for you at all.
The short version
Five companies build most of the hearing aids sold on earth, they own the brands that appear to compete with each other, and in several cases they sell nearly the same technology at two very different prices depending on how it reaches you. None of that makes their products bad. It just means the price on the tag is telling you about a distribution chain as much as it is telling you about a device.
If your hearing loss is mild to moderate and what you want is to follow conversation at a noisy table again, you can now buy a capable FDA-OTC device directly and skip most of that chain. Panda® Quantum is $349, ships free, and comes with a 45-day risk-free trial and a 5-year warranty.
Pay for the hearing aid, not the hallway.
Try Panda® Quantum — $349Market share figures are estimates reported by The Capitol Forum citing the American Economic Liberties Project. Brand-level prices are self-reported averages from HearingTracker's buyer survey and reflect what respondents paid, not manufacturer list prices. Corporate ownership and pending transactions can change. OTC hearing aids are intended for adults 18 and older with perceived mild to moderate hearing loss.